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Abstract
Purpose Genetic variation may influence women’s response
to ovarian stimulation therapy. The purpose of this study was
to investigate any effects of genetic variants in the anti-
Müllerian hormone (AMH) and AMH type II receptor genes
on ovarian response/treatment outcomes and on current
markers of ovarian reserve in individuals undergoing in vitro
fertilisation (IVF) treatment.
Methods In this prospective observational study, we geno-
typed the AMH c.146G>T, p.(Ile49Ser) and AMHR2 -
482A>G variants in 603 unrelated women undergoing their
first cycle of controlled ovarian stimulation for IVF and ICSI
(intracytoplasmic sperm injection) using gonadotrophins at a
tertiary referral centre for reproductive medicine. Pelvic ultra-
sound and blood hormone levels were taken on days 2–3 of the
cycle. Genotypes were determined using TaqMan allelic dis-
crimination assay. Regression analysis was performed to assess
the relationship between the genotypes and the ovarian reserve
markers (FSH, AMH, antral follicle count) and the early
outcomes of response (number of oocytes retrieved and gonad-
otropin dose) as well as the treatment outcome (live birth).
Results There were no significant associations between the
variants AMH c.146G>T and AMHR2 -482A>G with ovarian
response in terms of number of oocytes retrieved (p=0.08 and
p=0.64, respectively), live births (p=0.28 and p=0.52) and/
or markers of ovarian reserve.
Conclusions Genotyping of the AMH c.146G>Tand AMHR2
-482A>G polymorphisms does not provide additional useful
information as a predictor of ovarian reserve or ovarian re-
sponse and treatment outcomes.
Keywords Anti-Mullerian hormone . Antral follicle count .
Follicle-stimulating hormone . Pharmacogenetics . Ovarian
response . Ovarian hyperstimulation syndrome
Introduction
Ovarian response to stimulation with exogenous gonadotro-
phins during assisted reproductive techniques (ART) can
range from an inadequate response, which may result in cycle
cancellation, to a high response, which can put women at risk
of ovarian hyperstimulation syndrome (OHSS).
Capsule Genotyping of the AMH c.146G>T and AMHR2 -482A>G
polymorphisms does not provide additional useful information as a
predictor of ovarian reserve or ovarian response and treatment
outcomes.
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Markers of ovarian reserve, such as basal serum FSH (fol-
licle stimulating hormone) levels, estradiol, inhibin B, anti-
Müllerian hormone (AMH) levels and antral follicle count
(AFC), are currently used in clinical practice to predict re-
sponse to stimulation [1]. Of these markers, AMH has the
advantage of having relatively stable levels throughout the
menstrual cycle [2, 3] and is more accurate in providing infor-
mation on the expected ovarian response to controlled stimu-
lation [3, 4]. However, it is not highly predictive of extremes
of responses, and its value has been questioned [5].
AMH is a member of the transforming growth factor beta
superfamily and is produced by the granulosa cells of pre-
antral and small antral follicles in the ovary. It is highly
expressed in the developing follicles, but its expression dimin-
ishes at the stage for selection of the dominant follicle by FSH
[6]. It is used in clinical practice as a biomarker of ovarian
reserve [6]. AMH is expressed in granulosa cells and may
regulate FSH sensitivity in the ovary [7]. Therefore, it has
been proposed to have a role in influencing ovarian response
to stimulation [6]. It exerts its biological effects through the
receptor AMHR2, which is present on granulosa and theca
cells.
Considering the important role of the AMH signalling
pathway in regulating FSH sensitivity in the ovary and follic-
ular recruitment and selection, it is appropriate to consider that
variation in the genes encoding key proteins in the pathway
may influence ovarian response. Two polymorphisms, in
AMH c.146G>T, p.Ile49Ser (rs10407022) and AMH type II
receptor (AMHR2) -482A>G (rs2002555) genes, have been
genotyped in a number of studies. These two polymorphisms
have been associatedwith increased follicular phase oestradiol
levels [7], menopausal age related to parity [7–9], age at nat-
ural menopause [10], and severity of the polycystic ovary
syndrome (PCOS), in terms of follicle number and androgen
levels [11], and unexplained infertility [12]. Three previous
studies have considered these polymorphisms in relation to
their direct effects during ovarian stimulation in ART treat-
ment. A study of 191 women did not find a statistically sig-
nificant association between these polymorphisms and re-
sponse to ovarian stimulation [13]. In the second study of
151 women by Karagiorga et al., significant differences be-
tween certain subgroups following controlled ovarian stimu-
lation were found amongst women wild type for the AMH
polymorphism, in those with more than two previous IVF
attempts, basal serum FSH levels were lower (p= 0.012),
and in those with lower peak serum E2 levels, fertilisation
rates were higher (p=0.037) [14]. In addition, women wild
type for the AMHR2 polymorphism with more than two pre-
vious IVF attempts had a higher number of follicles, and
women with higher peak serum E2 levels required a lower
gonadotropin dose [14]. The third study of 186 infertile wom-
en by Peluso et al. showed an association between AMHR2
polymorphisms and FSH, estradiol and AMH levels, whilst
AMH polymorphisms were associated with the number of
embryos produced [15].
Given the differences in the previous reports, we undertook
a study in a previously collected and characterised cohort of
patients [15]. We genotyped AMH c.146G>T, p.(Ile49Ser) and
AMHR2 -482A>G in 603 unrelated women who underwent
ovarian stimulation using gonadotrophins and correlated geno-
types with ovarian reserve markers and treatment outcomes.
Materials and methods
Subjects and assays
A total of 603 women undergoing assessment prior to their first
IVF treatment cyclewere recruited to the study. Inclusion criteria
for the study were as follows: [1] presence of both ovaries [2],
<40 years of age [3], no use of hormone therapy in the 6 months
preceding the recruitment [4], no previous ovarian surgery or
pelvic radiation therapy [5], commencing first cycle IVF treat-
ment. In addition, the women had a bodymass index (BMI) >19
and <30 kg/m2 to satisfy eligibility criteria for government-
funded IVF treatment in Greater Manchester, UK [16]. The
protocol was approved by the South Manchester Research
Ethics Committee (REC ref no. 08/81003/212). Written in-
formed consent was obtained from all participants.
Baseline evaluation
On days 2 to 3 of a spontaneous menstrual cycle or after a
withdrawal bleed in anovulatory women, blood samples for
measurement of FSH and AMH levels were obtained by
venepuncture.
The FSH concentration was measured using specific im-
munoassay kits (Cobas; Roche Diagnostics). The intra-assay
and inter-assay coefficients of variations were 2.6 and 2.8 %,
respectively.
AMH levels were measured and determined by first gener-
ation ELISA provided by DSL (Oxford Bio Innovation). The
functional sensitivity of the assay was 0.05 ng/mL. Intra- and
inter-assay coefficients of variation were <5 and <5.5 %, re-
spectively. Conversion factor to ng/mL=pmol/L÷7.143.
AMH was used in treatment individualisation and is pre-
sented in the three triage bands (15.6 pmol/L, 15.6–28.6 pmol/
L, >28.6 pmol/L) used for clinical decision-making and allo-
cation to a treatment protocol at that time.
On days 2–3 of a spontaneous menstrual cycle within
3 months of commencing ovarian stimulation, a transvaginal
ultrasound scan was performed to assess the total number of
antral follicles measuring 2–5 mm in diameter and to confirm
normal anatomy of the pelvic organs. Intra-analysis coeffi-
cient of variation for follicular diameter measurements was
<5 %, and the lower limit of detection was 0.5 mm.
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IVF treatment protocol
Patients underwent either standard long downregulated cycles
using gonadotrophin-releasing hormone (GnRH) analogues
or short cycles using GnRH antagonists. The GnRH analogue
(buserelin acetate; Aventis Pharma Ltd) was administered at
the dose of 0.5 mg subcutaneously starting from the midluteal
phase of the preceding menstrual cycle. Ovarian stimulation
was effected with exogenous recombinant FSH (Puregon;
Organon Laboratories Ltd) or highly purified FSH
(Menopur; Ferring Pharmaceuticals). The GnRH analogue
was reduced to 0.25 mg from the first day of gonadotrophin
stimulation.
Patients on the antagonist cycle had gonadotrophin stimu-
lation initiated on day 2 of the cycle, continuing up to and
including the day of human chorionic gonadotrophin admin-
istration; the GnRH antagonist (Orgalutran; Organon
Laboratories) at a daily dose of 0.25 mg was initiated using
a fixed day-6 protocol.
Transvaginal ultrasounds were arranged on days 8 and 10,
then daily or on alternate days thereafter as required. Final
oocyte maturity was induced with 5000 IU of hCG (Pregnyl;
Organon Laboratories) in the presence of more than three
follicles of R17 mm. Oocyte retrieval was performed 34 to
36 hours after hCG administration, and a maximum of two
embryos was transferred 3 days later. Vaginal progesterone
pessaries (Cyclogest, 400 mg twice daily; Alpharma) were
used to support the luteal phase. We adopted standard stimu-
lation protocols across the groups.
Poor response was defined as the collection of less than
four oocytes at retrieval or cancellation of the cycle when
fewer than three mature follicles had developed. A normal
response was considered to be retrieval of 4 to 20 oocytes,
and over-response defined as >20 oocytes retrieved. Clinical
pregnancy was defined as the presence of a gestation sac con-
taining a foetal pole and foetal heart activity seen on
transvaginal scan from 6 weeks of gestation.
Genotyping
DNAwas extracted from blood samples using the Chemagen
Automated DNA Separation System. Genotypes for AMH
c.146G>T, p.(Ile49Ser) (rs10407022) and AMHR2 -482A>G
(rs2002555) were determined using the TaqMan SNP pre-
designed genotyping assay (assays ID C_25599842_10 and
C_1673084_10; Applied Biosystems).
Statistical analysis
Statistical analysis was performed using Rv2.15 (R
Development CoreTeam, 2013). Kruskall-Wallis and
Fisher’s exact tests were used to compare characteristics
across different genotypes.
Linear regression analysis was performed to assess the effect
of the AMH c.146G>T and AMHR2 -482A>G genotypes, rep-
resented as an allele number, on the log of ovarian reserve
markers (s-FSH, AFC and s-AMH), with adjustment for age
(as a 4 degree of freedom cubic spline) and BMI (as a linear
effect) and on the primary outcomes of response (gonadotro-
phin dose and log of number of oocytes retrieved) with adjust-
ment for age, BMI and treatment (s-AMH treatment band,
stimulation type and their interaction). s-AMH was used to
select the treatment, hence its inclusion as a treatment parame-
ter here. In addition, we also considered live birth and a dichot-
omous measure of over-response of >20 oocytes retrieved
(used in a previous similar study [15]), which we analysed
using analogous logistic regression models. There were no cy-
cles cancelled for over-response, and any cycles cancelled for
under-response were recorded as having yielded no oocytes.
A P value of <0.05 was considered statistically significant.
This study was performed using a previously collected and
characterised sample; therefore, there was no formal sample
size computation used to design the study. With genotypes
containing the minor alleles forming approximately one-third
of the sample, we have >80% power to detect small effect sizes
of 0.25 (in terms of the standard deviation between patients) or
odds ratios of around 0.6 for a live birth rate of 30 %.
Results
Complete clinical data were available for 560 women: 19were
excluded as they never proceeded to ovarian stimulation, and
no blood sample was obtained from 24 individuals.
Genotyping of AMH c.146G>T, p.(Ile49Ser) and AMHR2 -
482A>G variants was unsuccessful in 19 and 12 women,
respectively.
Tables 1 and 2 show the characteristics/demographics
for the women included in the analysis genotyped for
AMH c.146G>T, p.(Ile49Ser) and AMHR2 -482A>G, re-
spectively. There were no statistically significant differ-
ences in genotype frequencies with respect to BMI, dura-
tion of infertility or ovarian stimulation type. The one
borderline significant association with AMHR2 and age
(P = 0.041) would not be considered significant after
allowing for the number of characteristics tested.
Different allele frequencies in different ethnic groups were
noted for AMH c.146G>T; therefore, we performed a sep-
arate analysis for the largest ethnic group (BWhite^), not
presented here, which gave results consistent with the
analysis for the whole group presented below.
There were no statistically significant associations between
the measures of ovarian reserve (basal s-FSH, AFC and s-
AMH) and the AMH c.146G>T or AMHR2 -482A>G geno-
type groups, after adjusting for age, ethnicity and BMI
(Tables 3 and 4). There were also no significant associations
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between the genotypes and outcomes of ovarian response (in
terms of number of oocytes and embryos retrieved,
gonadotrophin dose and live birth rate) after adjustment for
age, BMI and treatment.
Table 1 Clinical characteristics
of women undergoing IVF
treatment by AMH genotype
AMH c.146G>T, p.(Ile49Ser) n = 541
Characteristic G/G
n= 24 (4 %)
G/T
n = 176 (33 %)
T/T
n = 341 (63 %)
P
Age (years) 35.3 (25.7–38.7) 33.2 (25.7–37.7) 33.3 (26.6–38.3) 0.06
BMI 23.1 (20–26.9) 24.1 (19.8–29.1) 23.7 (20.2–29.6) 0.26























































Note: values are in median (10th–90th percentile) or numbers (percentages of women with genotype)
P is from Fisher’s exact test or Kruskall-Wallis test
Table 2 Clinical characteristics
of women undergoing IVF
treatment by AMHR2 genotype
AMHR2 -482A>G n = 548
Characteristic A/A
n= 379 (69 %)
A/G
n = 152 (28 %)
G/G
n = 17 (3 %)
P
Age (years) 33.1 (26.1–38.1) 33.9 (27.4–38.0) 30.8 (25.9–35.9) 0.041
BMI 23.8 (20.1–29.2) 23.9 (20.0–29.5) 23.8 (20.5–29.2) 0.99























































Note: values are in median (10th–90th percentile) or numbers (percentages of women with genotype)
P is from Fisher’s exact test or Kruskall-Wallis test
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A dichotomous measure of response (>20 oocytes for high
response) was similarly analysed using equivalent logistic re-
gression models. We did not find a statistically significant
association between the AMH c.146G>T and AMHR2 -
482A>G variants and high response to ovarian stimulation
adjusted for age, ethnicity and BMI (per allele odds ratio
(OR) = 0.77, 95 % confidence interval (CI) = 0.4–1.47 for
AMH c.146G>T and OR=0.83, CI=0.41–1.65 for AMHR2
-482A>G, respectively).
Discussion
Controlled ovarian hyperstimulation in assisted reproduc-
tion involves the use of exogenous gonadotrophins, which
can result in an excessive response including OHSS, or
inadequate response leading to cycle cancellation. This
significant variability in response has been the focus of
many pharmacogenetic studies investigating single nucle-
otide polymorphisms (SNPs) as markers of ovarian reserve
and predictors of ovarian response in order to optimise and
individualise treatments.
Serum AMH levels are commonly used in current clinical
practice as markers of ovarian reserve and to predict the re-
sponse to controlled ovarian stimulation.
This large study investigated the association between the
AMH c.146G>T, p.(Ile49Ser) and AMHR2 -482A>G poly-
morphisms and ovarian response in women undergoing IVF
treatment. In addition, we included the most important clinical
outcome, live birth rate, as an outcome measure. We did not
identify any statistically significant differences (P<0.05) in
ovarian reserve markers and in treatment outcomes, including
the number of oocytes retrieved and live birth rates between
women with different AMH or AMHR2 genotypes, after
adjusting our results for age, BMI, stimulation protocol and
s-AMH band used to allocate treatment.
The study by Hanevik et al. similarly did not demonstrate
any association between the AMH and AMHR2 polymor-
phisms and high or low response to ovarian stimulation [13].
Further, our study considered additional outcomes and
markers of ovarian reserve.
Peluso et al. found in their study of 186 women that AMH
polymorphisms were associated with the number of embryos
produced and that AMHR2 polymorphisms were associated
with the ovarian reserve markers (AMH, FSH levels and
Table 3 Ovarian response and outcomes and markers of ovarian reserve by AMH genotype
AMH c.146G>T, p.(Ile49Ser) Adjusteda,b
G/G (n= 24) G/T (n= 176) T/T (n= 341) Change per allele (95 % CI)b P
Ovarian response outcomes
No. of oocytes retrieved 11 9 9 −0.09 0.08
(3–18) (3–20) (3–18) (−0.18–0.01)
No. of embryos 5 4 4 0.01 0.87
(0–12) (0–10) (0–9) (−0.10–0.12)
Gonadotrophin dose (IU) 2100 2700 2700 74 0.30
(1200–3435) (1500–3725) (1400–3750) (−66–215)
Live birth 7/24 51/176 92/341 0.83 0.28
(29 %) (29 %) (27 %) (0.58–1.17)
Under-response (<4 oocytes) 3/24 23/176 46/341 1.09 0.70
(12 %) (13 %) (13 %) (0.69–1.74)
Over-response
(>20 oocytes)
1/24 16/176 18/341 0.77 0.42
(4 %) (9 %) (5 %) (0.4–1.47)
Ovarian reserve
7.0 7.0 6.6 −0.03 0.35
s-FSH (IU/L) (4.5–10.8) (4.7–10.4) (4.6–9.8) (−0.08–0.03)
AFC 15 13 13 0.01 0.75
(2–5 mm) (6.4–31) (8–21) (8–24) (−0.06–0.08)
s-AMH (pmol/L) 12.9 14.5 15.7 0.06 0.32
(6.0–49.5) (5.5–37.1) (5.1–42.4) (−0.06–0.17)
Note: Outcome values are median (10th–90th percentile), effect sizes shown with 95 % CI
aAdjusting for age as cubic spline and BMI as linear effect, ethnicity as four groups, with oocyte and embryo number, s-FSH, AFC and s-AMH being
log-transformed. Effect size is change in (log) value per allele for the continuous variables or odds ratios for live birth and under/over-response
b Response outcomes additionally adjusted for treatment as AMH treatment band, stimulation type and their interaction
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antral follicle count). However, they did not specify if any
adjustments were made in their logistic regression model
and so a direct comparison of the results is difficult.
Differences in results between association studies may be
due to different allelic frequencies between ethnic groups. We
did note differences in the allele frequencies between the eth-
nic groups recruited to our study and so performed a further
analysis considering the dichotomous variables (over/under
response) for the largest group (white British individuals) as
per the previous study [13]. No significant associations were
determined, indicating that it is unlikely that our combined
analysis masked an association specific to a discrete ethnic
group. Further, the allelic distributions we observed were sim-
ilar to those found in Brazilian [Peluso et al.], Greek
[Karagiorga et al.] and Norwegian [Hanevik et al.] cohorts.
Other factors that may explain the lack of consensus
amongst the different studies that have investigated relation-
ships between AMH and AMHR2 genotypes and controlled
ovarian stimulation include differences in ovarian stimulation
protocols used, the design of the study and the outcome mea-
sures. In the study by Karagiorga et al., significant associa-
tions were revealed only after subgroup analyses were per-
formed based on age, AMH levels, peak E2 serum levels
and number of IVF cycles. In addition, the outcome measure
used in their study was different, as they compared number of
follicles rather than number of oocytes retrieved used for our
study.
Although the AMH and AMHR2 variants were not associ-
ated with ovarian response in this study, Boudjenah et al.
found that it was only the combination of AMH and FSHR
variants which correlated with the number of mature oocytes
produced during controlled ovarian stimulation with recombi-
nant FSH [17].
In conclusion, when considering the development of inte-
grative clinical algorithms for individual FSH doses, our re-
sults indicate that genotyping AMH c.146G>T and AMHR2 -
482A>G variants does not provide useful information as a
predictor of response to ovarian stimulation and treatment
outcomes.
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creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
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Table 4 Ovarian response and outcomes, and markers of ovarian reserve by AMHr2 genotype
AMHR2 -482A>G Adjusteda,b
A/A (n= 379) A/G (n= 152) G/G (n= 17) Change per allele (95 % CI)b P
Ovarian response outcomes
No. of oocytes retrieved 9 8 10 0.02 0.64
(3–18) (3–18) (3–16) (−0.08–0.12)
No. of embryos 4 4 4 0.09 0.20
(0–9) (1–10) (0–9) (−0.02–0.21)
Gonadotrophin dose (IU) 2700 2475 3000 36 0.63
(1350–3750) (1428–3600) (1710–3300) (−110–183)
Live birth 103/379 43/152 6/17 1.12 0.52
(27 %) (28 %) (35 %) (0.79–1.60)
Under-response (<4 oocytes) 55/379 17/152 2/17 0.82 0.44
(15 %) (11 %) (12 %) (0.49–1.37)
Over-response
(>20 oocytes)
25/379 10/152 0/17 0.83 0.59
(7 %) (7 %) (0 %) (0.41–1.65)
Ovarian reserve
s-FSH (IU/L) 6.8 6.7 6.2 −0.02 0.50
(4.6–10.1) (4.6–10.0) (4.9–9.2) (−0.07–0.04)
AFC (2–5 mm) 13 13 14 −0.01 0.69
(8–23) (8–20) (10–31) (−0.08–0.05)
s-AMH (pmol/L) 15.3 14.7 24.7 0.04 0.49
(5.3–42.6) (5.2–36.0) (6.0–63.2) (−0.08–0.16)
Note: Outcome values are median (10th–90th percentile), effect sizes shown with 95 % CI
AMH anti-Mullerian hormone, BMI body mass index, FSH follicle-stimulating hormone
aAdjusting for age as cubic spline and BMI as linear effect, ethnicity as four groups, with oocyte and embryo number, s-FSH, AFC and s-AMH being
log-transformed. Effect size is change in (log) value per allele for the continuous variables or odds ratios for live birth and under/over-response
b Response outcomes additionally adjusted for treatment as AMH treatment band, stimulation type and their interaction
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